Compare ARK Genomic Revolution ETF (ARKG) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Davita Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Davita Inc trades at $233.6 (market cap $14.94B). Which is the better fit depends on your goals.
| ARKG | DVA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $235.71 |
52-Week Low | $23.09 | $103.87 |
Market Cap | — | $14.94B |
Enterprise Value | — | $27.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
DaVita (DVA) trades at $232.80, up 1.45% on the day, with a bullish technical signal and strong institutional backing. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. Revenue growth is steady, reaching $13.64B in 2025, though net income margin dipped to 5.47%. The stock is supported by positive analyst coverage and expansion in kidney care services, including AI-driven scheduling improvements. Current price sits near resistance at $233, with RSI levels indicating potential overbought conditions.
Outlook remains cautiously optimistic given DVA's market leadership and operational improvements, but high debt levels and valuation metrics pose risks. Analyst consensus suggests moderate upside to the $222.80 price target, with 39% buy ratings. Key risks include regulatory changes in healthcare and execution challenges in growth initiatives. The stock's proximity to yearly highs warrants monitoring for pullback opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
